Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil

ZD1839 (‘Iressa’), an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is currently being investigated in clinical trials as a treatment for cancer. ‘Iressa’ is a trademark of the AstraZeneca group of companies. We have previously demonstrated a synergistic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Magné, N, Fischel, J-L, Tiffon, C, Formento, P, Dubreuil, A, Renée, N, Formento, J-L, Francoual, M, Ciccolini, J, Etienne, M-C, Milano, G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2003
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2394392/
https://ncbi.nlm.nih.gov/pubmed/12888834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601131
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados